REG - Polarean Imaging PLC - Strategic review and consideration of AIM listing

Polarean ImagingAnnouncement

22/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2856Ea&default-theme=true

RNS Number : 2856E  Polarean Imaging PLC  22 October 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

Strategic Review and Consideration of AIM Listing Status

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical technology
company and global leader in functional lung imaging using hyperpolarised
Xenon MRI, announces that its Board of Directors is undertaking a strategic
review of the Company's future direction and organisational structure.

 

The Board recognises that the UK public market environment for small-cap
MedTech companies remains highly challenging, characterised by persistent
undervaluation, limited liquidity, and the ongoing costs associated with
maintaining a public listing. With shares frequently trading below their
intrinsic value and market activity remaining subdued, investors continue to
face difficulties executing trades efficiently. At the same time, the Company
requires additional capital to advance the development and commercialisation
of its technology.

 

In light of these factors, the Board is evaluating all available options to
maximise long-term shareholder value, including identifying opportunities to
further reduce operational costs while maintaining strict financial
discipline. Among the options under consideration is the potential
cancellation of the admission of the Company's ordinary shares to trading on
AIM ("Cancellation"). After careful deliberation, the Board believes that,
under certain circumstances, a transition to a private company structure could
reduce operational expenses, provide greater strategic flexibility, and
broaden access to capital on more favourable terms.

 

No decision has been made at this stage. Should the Board determine that
pursuing a Cancellation and re-registration of the Company as a private
company is in the best interests of shareholders, a detailed circular setting
out the background, rationale, and implications of such a proposal will be
sent to shareholders. Any Cancellation would require the approval of not less
than 75 percent of votes cast by shareholders at a duly convened general
meeting, in accordance with Rule 41 of the AIM Rules for Companies.

 

The Company remains committed to advancing its mission of revolutionising
pulmonary medicine through Xenon MRI and to continuing commercial growth while
this review is ongoing. A further announcement will be made if and when the
Board decides to proceed with any specific course of action.

 

Enquiries:

 

 Polarean Imaging plc                                                  www.polarean.com
                                                                       (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean.com)
                                                                       / www.polarean-ir.com
                                                                       (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean-ir.com)
                                                                         
 Christopher von Jako, Ph.D., Chief Executive Officer                                                   Via Walbrook PR  

 Charles Osborne, Chief Financial Officer                                                                 
                                                                                                                                          
 Stifel (NOMAD and Sole Corporate Broker)                                                                                                +44 (0)20 7710 7600 
 Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good                                                                                                                    
                                                                        
 Walbrook PR               Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Anna Dunphy / Paul McManus / Marcus Ulker             Mob: +44 (0)7876741001 / +44 (0) 7980541893 / +44 (0)7867984 082

 

 

 

 

 

About Polarean

 

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform.

 

For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDMBBRTMTMTBTA



            Copyright 2019 Regulatory News Service, all rights reserved